The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
WITHDRAWN: Evaluating PSA and PSMA responses of enzalutamide with or without a tumor targeting immunocytokine (PDS01ADC) in patients with PSMA-positive recurrent prostate cancer without testosterone-lowering therapy.
 
Monique Williams
No Relationships to Disclose
 
Melissa Abel
No Relationships to Disclose
 
Amy Hankin
Stock and Other Ownership Interests - Amgen; Medtronic
 
Lisa Cordes
No Relationships to Disclose
 
Ruchi Patel
No Relationships to Disclose
 
Katherine Lee-Wisdom
No Relationships to Disclose
 
Megan Hausler
No Relationships to Disclose
 
Jeanny Aragon-Ching
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Merck KGaA; Merck/Pfizer; Pfizer/EMD Serono
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Pfizer; Pfizer/Myovant; Sanofi; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono
 
Philip Arlen
No Relationships to Disclose
 
Renee Donahue
No Relationships to Disclose
 
Yo-Ting Tsai
No Relationships to Disclose
 
Jeffrey Schlom
No Relationships to Disclose
 
James Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
William Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
 
Fatima Karzai
No Relationships to Disclose
 
Ravi Madan
Research Funding - Bayer